Anti-Human CD3E Recombinant Antibody (TAB-159)

Customer Review

There are currently no Customer reviews or questions for TAB-159. Click the button above to contact us or submit your feedback about this product.

Michael White
07.Nov,23

Ideal for CD3 Research

The Anti-Human CD3 Therapeutic Antibody (Teplizumab) has been a fantastic addition to our CD3 studies. Its specificity and sensitivity are outstanding, consistently providing clear results. This antibody has become essential for our research, improving the accuracy and reliability of our assays.

Laura Scott
11.Oct,22

Reliable in Immunoassays

We incorporated this antibody into our immunoassays, and it has been a great asset. The specificity for CD3 is precise, allowing for accurate detection and analysis. The reliable performance has made it an invaluable tool in our lab.

Brian Young
28.Jun,21

Consistent and Effective

This antibody has proven to be consistent and dependable in our assays. The high-quality, reproducible results have significantly improved our experiments, making it a crucial part of our research toolkit. The strong affinity and specificity for CD3 have been particularly beneficial.

Q&As

1. Is the anti-Human CD3 therapeutic antibody Teplizumab suitable for use in Western blotting?

   A: Yes, the anti-Human CD3 therapeutic antibody Teplizumab (TAB-159) is suitable for use in Western blotting. It provides specific binding to CD3, allowing for reliable detection in Western blot assays.

2. What are the storage recommendations for the anti-Human CD3 therapeutic antibody Teplizumab?

   A: The recommended storage condition for the anti-Human CD3 therapeutic antibody Teplizumab (TAB-159) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

3. Can the anti-Human CD3 therapeutic antibody Teplizumab be used in immunoprecipitation assays?

   A: Yes, the anti-Human CD3 therapeutic antibody Teplizumab (TAB-159) can be used in immunoprecipitation assays. It provides specific binding to CD3, enabling the successful precipitation of the target protein from complex mixtures.

4. Is the anti-Human CD3 therapeutic antibody Teplizumab effective in ELISA applications?

   A: Yes, the anti-Human CD3 therapeutic antibody Teplizumab (TAB-159) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD3.

5. What is the optimal dilution for using the anti-Human CD3 therapeutic antibody Teplizumab in immunofluorescence?

   A: The optimal dilution for using the anti-Human CD3 therapeutic antibody Teplizumab (TAB-159) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.

View the frequently asked questions answered by Creative Biolabs Support.

Citations

1. Tran Quang, Christine, et al. "Preclinical efficacy of humanized, non-FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia." Blood, The Journal of the American Society of Hematology 136.11 (2020): 1298-1302. https://doi.org/10.1182/blood.2019003801
   This study investigates the use of humanized, non-Fcg receptor-binding monoclonal antibodies (mAbs) targeting CD3 in the treatment of T-cell acute lymphoblastic leukemia (T-ALL). T-ALL is a highly aggressive malignancy characterized by the proliferation of T-cell precursors. Traditional chemotherapy results in high cure rates in children but less success in adults. This study explores the antileukemic properties of humanized anti-CD3 mAbs, particularly hOKT3g1[Ala/Ala] and foralumab, in xenograft models of T-ALL. These antibodies demonstrated significant antileukemic activity, prolonged host survival, and cooperated with chemotherapy to enhance treatment efficacy, showing minor, manageable adverse effects.
   Creative Biolabs provided essential antibodies for this study, including foralumab (Cat#: BPTG-061) and teplizumab (Cat#: TAB-159) as an alternative source of hOKT3γ1[Ala/Ala]. These antibodies, designed to prevent FcγR binding and reduce immune cell activation, were crucial in demonstrating the potent antileukemic activity in T-cell acute lymphoblastic leukemia (T-ALL) models. Their contribution enabled the researchers to validate the efficacy of non-FcγR-binding anti-CD3 antibodies in reducing leukemia burden and improving survival in xenograft models, thus supporting the potential of these engineered antibodies as a novel therapeutic strategy for T-ALL.

Cite This Product

To accurately reference this product in your publication, please use the following citation information:

(Creative Biolabs Cat# TAB-159, RRID: AB_3111841)

Submit Your Publication

Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.

Biosimilar Overview

Please refer to Teplizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Teplizumab.

Downloadable Resources

Download resources about recombinant antibody development and antibody engineering to boost your research.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Datasheet

MSDS

COA

To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.

Protocol & Troubleshooting

We have outlined the assay protocols, covering reagents, solutions, procedures, and troubleshooting tips for common issues in order to better assist clients in conducting experiments with our products. View the full list of Protocol & Troubleshooting.

See other products for "CD3E"

Select a product category from the dropdown menu below to view related products.